← Leaderboards
Christian Furlan Freguia
Rise Therapeutics, Llc
$4,372,588
Attributed
$8,462,661
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2022–25$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$8,462,661 · 5
By mechanism
R44$8,180,147 · 4
R43$282,514 · 1
Top collaborators
- Gary Fanger10 shared
Most similar at Rise Therapeutics, Llc
Same institution · by research overlap
- Gary Fanger$26,547,866
- Sathyanarayana Janardhanan$688,972
Others in their field
Other Rising Stars on “Immune”
- Angee Greer · Ppd Development Lp$82,531,927
- Rhea Coler · Seattle Children'S Hospital$35,184,139
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Cathie Snyder · Rho Federal Systems Division, Inc.$13,500,724
- Jason Dickens · Duke University$12,259,409
- Suma Babu · Massachusetts General Hospital$11,004,714
Research focus
ImmuneMediatingOralSafetyPharmaceutical PreparationsIntestinesGut MicrobiomeProbioticsAffectImmunologicsInflammatoryLifeMicrobiomeBiological Response Modifier TherapyCellsNovel StrategiesCostAntigensCommercializationCurative TreatmentsClinical TrialsIncidenceGeneticDose
Grant awards (11)
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis$827,713
R44 · FY2025 · AI · contact PI
R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes$995,869
R44 · FY2024 · DK · contact PI
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)$984,405
R44 · FY2024 · AI · contact PI
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis$956,049
R44 · FY2024 · AI · contact PI
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)$1,026,596
R44 · FY2023 · AI · contact PI
R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes$1,000,000
R44 · FY2023 · DK · contact PI
A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes$983,580
R44 · FY2023 · DK · contact PI
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis$306,499
R44 · FY2023 · AI · contact PI
A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes$1,021,316
R44 · FY2022 · DK · contact PI
A Novel Probiotic Drug Delivery Platform for Oral Administration of Protein-Based Therapies$282,514
R43 · FY2022 · TR · contact PI
A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes$78,120
R44 · FY2022 · DK · contact PI